BeOne Medicines AG, an oncology-focused enterprise headquartered in Basel, Switzerland, was established in 2010. This company is actively involved in the exploration and advancement of a diverse range of therapeutic solutions for cancer patients across key global regions, including the United States, China, Europe, and other international markets. Its current commercial portfolio features several significant treatments: BRUKINSA: A small molecule designed to inhibit Bruton's Tyrosine Kinase (BTK), indicated for various blood cancers. TEVIMBRA: An anti-PD-1 antibody immunotherapy utilized in the treatment of both solid tumors and blood cancers. PARTRUVIX: A selective small molecule inhibitor targeting the PARP1 and PARP2 enzymes, currently undergoing evaluation both as a standalone therapy and in combination approaches for different solid tumors. Beyond these marketed products, BeOne Medicines maintains a robust pipeline of clinical-stage assets. These encompass a broad spectrum of novel agents, such as small molecule inhibitors (e.g., targeting Bcl-2, BTK, TIGIT, MAT2A, PRMT5, KRAS, CDK4, CDK2, IRAK4, HPK-1), advanced antibody-drug conjugates (ADCs) aimed at various targets (e.g., B7H3, FGFR2b, CEA, B7H4), and sophisticated bispecific antibodies (e.g., HER2-targeted, anti-GPC3x4-1BB, anti-MUC1xCD16A, anti-EGFRxMET). Additionally, the company is progressing multiple research programs within its preclinical development phase. To bolster its research and development initiatives, BeOne Medicines has established strategic alliances with prominent pharmaceutical entities, including Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company, initially known as BeiGene, Ltd., is slated to officially adopt the name BeOne Medicines AG in May 2025.
前收盤價
US$390.94
−US$8.76 · -2.19%
盤中時間採用ET。市場資料可能有所延遲。
BeOne Medicines AG, an oncology-focused enterprise headquartered in Basel, Switzerland, was established in 2010. This company is actively involved in the exploration and advancement of a diverse range of therapeutic solutions for cancer patients across key global regions, including the United States, China, Europe, and other international markets. Its current commercial portfolio features several significant treatments: BRUKINSA: A small molecule designed to inhibit Bruton's Tyrosine Kinase (BTK), indicated for various blood cancers. TEVIMBRA: An anti-PD-1 antibody immunotherapy utilized in the treatment of both solid tumors and blood cancers. PARTRUVIX: A selective small molecule inhibitor targeting the PARP1 and PARP2 enzymes, currently undergoing evaluation both as a standalone therapy and in combination approaches for different solid tumors. Beyond these marketed products, BeOne Medicines maintains a robust pipeline of clinical-stage assets. These encompass a broad spectrum of novel agents, such as small molecule inhibitors (e.g., targeting Bcl-2, BTK, TIGIT, MAT2A, PRMT5, KRAS, CDK4, CDK2, IRAK4, HPK-1), advanced antibody-drug conjugates (ADCs) aimed at various targets (e.g., B7H3, FGFR2b, CEA, B7H4), and sophisticated bispecific antibodies (e.g., HER2-targeted, anti-GPC3x4-1BB, anti-MUC1xCD16A, anti-EGFRxMET). Additionally, the company is progressing multiple research programs within its preclinical development phase. To bolster its research and development initiatives, BeOne Medicines has established strategic alliances with prominent pharmaceutical entities, including Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company, initially known as BeiGene, Ltd., is slated to officially adopt the name BeOne Medicines AG in May 2025.
日內區間
目前US$390.94
52週區間
目前US$390.94
盤中時間採用ET。市場資料可能有所延遲。
BeOne Medicines AG, an oncology-focused enterprise headquartered in Basel, Switzerland, was established in 2010. This company is actively involved in the exploration and advancement of a diverse range of therapeutic solutions for cancer patients across key global regions, including the United States, China, Europe, and other international markets. Its current commercial portfolio features several significant treatments: BRUKINSA: A small molecule designed to inhibit Bruton's Tyrosine Kinase (BTK), indicated for various blood cancers. TEVIMBRA: An anti-PD-1 antibody immunotherapy utilized in the treatment of both solid tumors and blood cancers. PARTRUVIX: A selective small molecule inhibitor targeting the PARP1 and PARP2 enzymes, currently undergoing evaluation both as a standalone therapy and in combination approaches for different solid tumors. Beyond these marketed products, BeOne Medicines maintains a robust pipeline of clinical-stage assets. These encompass a broad spectrum of novel agents, such as small molecule inhibitors (e.g., targeting Bcl-2, BTK, TIGIT, MAT2A, PRMT5, KRAS, CDK4, CDK2, IRAK4, HPK-1), advanced antibody-drug conjugates (ADCs) aimed at various targets (e.g., B7H3, FGFR2b, CEA, B7H4), and sophisticated bispecific antibodies (e.g., HER2-targeted, anti-GPC3x4-1BB, anti-MUC1xCD16A, anti-EGFRxMET). Additionally, the company is progressing multiple research programs within its preclinical development phase. To bolster its research and development initiatives, BeOne Medicines has established strategic alliances with prominent pharmaceutical entities, including Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company, initially known as BeiGene, Ltd., is slated to officially adopt the name BeOne Medicines AG in May 2025.
日內區間
目前US$390.94
52週區間
目前US$390.94
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 53.43億 USD | 38.1億 USD | 24.59億 USD | 14.16億 USD | 11.76億 USD |
| 銷貨成本 | 6.69億 USD | 5.94億 USD | 3.8億 USD | 2.86億 USD | 1.65億 USD |
| 毛利 | 46.74億 USD | 32.16億 USD | 20.79億 USD | 11.29億 USD | 10.11億 USD |
| 研究與開發 | 21.46億 USD | 19.53億 USD | 17.79億 USD | 16.41億 USD | 14.59億 USD |
| 銷售、一般及管理費用 | 20.81億 USD | 18.31億 USD | 15.08億 USD | 12.79億 USD | 9.9億 USD |
| 營業費用 | 42.27億 USD | 37.84億 USD | 32.87億 USD | 29.19億 USD | 24.5億 USD |
| 利息收入 | 7050.5萬 USD | 4783.6萬 USD | 7400.9萬 USD | 5248萬 USD | 1575.7萬 USD |
| 利息支出 | 5823.4萬 USD | — | — | — | — |
| 折舊和攤銷 | 1.42億 USD | 1.72億 USD | 8767.5萬 USD | 6627.8萬 USD | 4645.7萬 USD |
| 營業利益 | 4.47億 USD | −5.68億 USD | −12.08億 USD | −17.9億 USD | −14.39億 USD |
| 淨利 | 2.87億 USD | −6.45億 USD | −8.82億 USD | −20.04億 USD | −14.58億 USD |
公司資料更新於 2026年11月22日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動,並非 GoAI 建議。
平均目標
US$426.5
上漲空間 9.10%報告持有此股票曝險的交易所交易基金。
iShares Biotechnology ETFIBB2.55億2.43%105.27億 USD0.44%US$199.54-2.05%
First Trust NYSE Arca Biotechnology Index FundFBT1.09億3.80%28.67億 USD0.55%US$257-2.20%
Capital Group Global Growth Equity ETFCGGO9693萬0.85%113.97億 USD0.47%US$34.38-4.34%
Global X China Biotech ETF (HKD)2820.HK6543.13萬12.33%6.22億 HKD0.68%HK$63.56-4.22%
Capital Group Global Equity ETFCGGE2615.84萬0.82%32.03億 USD0.47%US$31.25-3.67%
Capital Group New Geography Equity ETFCGNG1923.4萬0.67%28.62億 USD0.64%US$29.91-4.13%
Capital Group International Equity ETFCGIE1648萬0.70%23.48億 USD0.54%US$33.33-3.22%
VanEck Biotech ETFBBH1540.12萬3.03%5.03億 USD0.35%US$239.49-1.31%
iShares Biotechnology ETFIBB
First Trust NYSE Arca Biotechnology Index FundFBT
Capital Group Global Growth Equity ETFCGGO
Global X China Biotech ETF (HKD)2820.HK
Capital Group Global Equity ETFCGGE
Capital Group New Geography Equity ETFCGNG
Capital Group International Equity ETFCGIE
VanEck Biotech ETFBBHAI 生成內容及延遲市場資料僅供資訊與教育用途,不構成投資建議。